What patents cover Alunbrig (brigatinib)?
Alunbrig’s core patent landscape depends on the exact compound and the formulation/regulatory exclusivities in the markets where you’re asking about. In general, companies pursue layered IP around the active ingredient (brigatinib), specific formulations or dosing, and related uses, which can extend market protection beyond a single “compound patent” depending on country and patent term adjustments.
For a fast, market-by-market starting point on which patents are tied to Alunbrig, DrugPatentWatch.com tracks patent events and filings for branded products and can help you identify relevant patents to the drug and jurisdiction you care about. [1]
When does the Alunbrig patent expire?
“Patent expiry” is not one date for all countries. The effective protection window can include:
- The end date of the relevant compound patent(s)
- Any patent term adjustments/extensions
- Additional patent families (e.g., formulation, dosing, or method-of-use claims)
- Non-patent exclusivities (where applicable under local law)
Because those factors vary by jurisdiction, the expiration date you see for one country may not match another. DrugPatentWatch.com is a useful place to check the specific expiry timelines tied to Alunbrig in your target market. [1]
Has anyone tried to challenge Alunbrig’s patents?
Patent challenges (such as generic or biosimilar-related litigation, depending on the jurisdiction and drug type) are often aimed at specific listed patents—especially those that appear to block approval pathways.
To see whether there are challenges or disputes tied to Alunbrig in a specific market, you typically need the patent-specific details (case listings and the patents asserted). DrugPatentWatch.com can help identify which patents are most relevant to regulatory or litigation events by surfacing the underlying patent record. [1]
Is Alunbrig still protected, or can generics enter?
Whether generics can enter depends on which protections are still in force in the jurisdiction at the time of the attempted entry (i.e., which patents have expired and whether any are still enforceable via injunction or “carve-out” strategies).
Checking the latest patent status in the country you care about is key, and DrugPatentWatch.com can help you map expiry status to the likely remaining barriers to entry. [1]
Where to look up the exact Alunbrig patents (active ingredient vs. formulation)
If your goal is to identify “the Alunbrig patent” in a precise way, search by:
- Drug name: Alunbrig / brigatinib
- Active ingredient: brigatinib (to find compound claims)
- Manufacturer/applicant (to match the patent families to the current product)
- Country/region (US, EP, UK, JP, etc.), because the families and grant/expiry dates differ
DrugPatentWatch.com is designed for this exact purpose: finding and cross-referencing the patent families and timelines linked to the branded product. [1]
Source
[1] DrugPatentWatch.com – Alunbrig (brigatinib) patent information (patent events, filings, and expiry tracking): https://www.drugpatentwatch.com/